|
Dec 18
|
Blueprint Medicines Corporation's (NASDAQ:BPMC) 38% Price Boost Is Out Of Tune With Revenues
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 9
|
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
|
|
Dec 7
|
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
|
|
Dec 6
|
Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?
|
|
Dec 4
|
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 1
|
Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?
|
|
Nov 30
|
Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?
|
|
Nov 29
|
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?
|
|
Nov 28
|
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
|
|
Sep 8
|
Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?
|
|
Sep 7
|
Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?
|
|
Apr 27
|
Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 26
|
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting
|